Schwabe Group
Klaus Uedelhofen has a diverse work experience starting from 1996. Klaus began their career as a Consultant at Roland Berger Strategy Consultants and worked there until December 2003. From 2003 to 2005, they served as the President & CEO of Liwena Pharma. In 2005, they joined Accenture as a Consultant and stayed until 2006. Klaus then became a Founding Partner at Cepton GmbH from 2006 to 2010. In 2011, Klaus joined Nature's Way as a Senior Vice President and also took on the role of SVP Strategic Planning & Business Development. Klaus worked there until 2018 when they moved to the Schwabe Group. At the Schwabe Group, Klaus held various leadership positions including Head Global Strategy & Business Development and Executive Vice President Global Strategy & Business Development. Klaus is currently the Senior Vice President Strategy & Global Business Development of the Schwabe Group's subsidiary, Nature's Way.
Klaus Uedelhofen has an extensive education history. Klaus completed their Abitur at Friedrich Dessauer Gymnasium from 1980 to 1989. Prior to that, they attended Grundschule Bellenweg from 1977 to 1980. In higher education, Klaus earned a Diplom Kaufmann degree in Business, Management, Marketing, and Related Support Services from the University of Tübingen between 1992 and 1996. Before that, they obtained a Bachelor of Business Administration (BBA) from The Philipp University of Marburg from 1990 to 1992.
This person is not in any offices
Schwabe Group
The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the Group focus on plants as the basis for developing pharmaceuticals and health products. The original form of the Group’s parent company, which is now Dr. Willmar Schwabe GmbH & Co. KG, is one of the oldest pharmaceutical manufacturers in Europe and has a company history dating back over 150 years. We do so by researching and developing plant-based medicines and health-care products. Our goal is to create value through innovation. We believe that innovative phytomedicines will become increasingly important over the next few decades. By influencing several target systems in the body at the same time, they may be more appropriate for patients suffering from complex or age-related diseases than is the “silver bullet” approach of synthetic medicines. In the future, phytomedicines will help people, worldwide, to lead a sustainable, productive and healthy life. We are actively shaping the company’s international future in a changing and challenging global market. Our goal is to maintain our market-leadership in phytomedicines by introducing our products into new markets, expanding our network of affiliates and distribution partners, and providing more extensive access to our health-care solutions. The commitment, experience and creativity of our employees are the source of our success. At Schwabe Pharmaceuticals we share a common vision: “From Nature. For Health”. We would like to invite you to learn more about this vision and our company on this website.